Pre-clinical data management, from RS3 to ChemAxon Compound Registration

presentation · 10 months ago
by Sofia Karlström (ChemAxon, Medivir)

Medivir has recently migrated all its chemical structures (small molecules) and in vitro assay result data from the out-of-date Accelrys RS3 platform into two separate systems - ChemAxon´s Compound Registration for the chemistry, and The Edge´s Biorails for the assay results. A key element of the project has been the integration with Certara´s D360. The new solution went into production in May 2017. We will describe the challenges encountered in the project and the solutions developed by the project team, and provide examples of how we use the Compound Registration system today; including the ways in which data is displayed and analyzed in Certara´s D360.

Medivir has recently migrated all its chemical structures (small molecules) and in vitro assay result data from the out-of-date Accelrys RS3 platform into two separate systems, ChemAxon´s Compound Registration for the chemistry, and The Edge´s Biorails for the assay results. A key element of the project has been the integration with Certara´s D360. The new solution went into production in May 2017. We will describe the challenges encountered in the project and the solutions developed by the project team, and provide examples of how we use the Compound Registration system today, including the ways in which data is displayed and analyzed in Certara´s D360.

Download slides